Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | We know many researchers are concerned about recent changes in government policy on visa routes into the UK, especially regarding the skilled worker visa. Sue Russell, Senior Policy and Governance Manager, has written an update on the global talent visa, looking at why it’s a useful route for researchers to use, addressing some misconceptions about it, and clarifying how it’s accessible for Cancer Research UK-funded researchers at different career stages. |
| |
| |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | 31 December Applications accepted all year round |
|
---|
| | | | 31 December Applications accepted all year round |
|
---|
| | | | 31 December Applications accepted all year round |
|
---|
|
| |
|
|
New in Nature Cancer : Mutations in mitochondrial DNA could help patients respond to treatment |
| Mahnoor Mahmood, Payam Gammage (both CRUK Scotland Institute), Ed Reznik (Memorial Sloan Kettering Cancer Centre) and colleagues explore the functional impact of mitochondrial DNA (mtDNA) mutations on tumour biology and cancer metabolism in a study published in Nature Cancer. They developed mtDNA base editing technology, which is now being patented by our innovation arm Cancer Research Horizons, to engineer recurrent truncating mutations in murine models of melanoma, which in turn promoted an anti-tumour immune response. They found that tumours with mtDNA mutations were sensitised to immune checkpoint blockade. Patient lesions with high levels of mtDNA mutations were up to two and a half times more likely to respond to nivolumab, an immunotherapy drug which acts by restoring a patient's tumour-specific T-cell response.
|
| |
|
|
|
| | In 2024 the Black cancer community will come together for a two-day conference on June 20-21 in Bethesda, Maryland, USA. The meeting will celebrate Black contributions in cancer research and be a space for students and early-career researchers to connect, facilitating mentorship to build strong support networks for the next generation of black researchers. The first Black in Cancer Conference in 2022 saw more than 220 Black cancer researchers meet in London to collaborate, network and celebrate. This year's agenda includes seminars, panel discussions and networking sessions, covering topics like AI and the future of Black cancer care, diversity in clinical trials and workforce diversity and pathway programs. | |
| | | | Join us for our first annual cancer prevention research conference taking place on 25-27 June in Boston. This event will feature sessions exploring health inequalities in cancer incidence and prevention, mechanistic insights in prevention strategies, and precision prevention in high-risk populations. Stay up to date with the programme and latest confirmed speakers on our website and by following #PrevConf24 on social media. | |
|
---|
|
|
|
|
| Unlock the potential of your MedTech or AI Idea |
| Would you like to transform your creative technology or concept into a thriving health-tech enterprise that addresses critical needs for cancer patients? Join our Cancer Tech Accelerator and propel your innovative solutions for the early detection, diagnosis, monitoring, or treatment of cancer. Embark on your entrepreneurial journey with our nine-month programme, featuring a virtual bootcamp, immersive workshops, interactive sessions, and focused learning experiences. In collaboration with our partners Cancer Research Horizons, Capital Enterprise, Blood Cancer UK, LifeArc, The Brain Tumour Charity, Roche, and HGF Limited, our programme promises an opportunity to progress your idea. Apply by 16 February. |
| |
|
|
|
|
|
| | In the latest special episode of One in Two: a Manchester Cancer Research Podcast, Emma Woodward from Manchester University NHS Foundation Trust and patient Nick Brown discussed how the ATLAS study could improve cancer early detection in carriers of Li Fraumeni Syndrome (LFS). Tune in to hear how LFS affected Nick and his family, what the current screening regime for LFS is, and how the ATLAS study run by Emma in collaboration with Ontario Institute for Cancer Research in Canada is changing cancer detection in LFS.
| |
| | | | Join the multidisciplinary workshops on childhood blood cancers on 3–6 May in Dusseldorf, uniting an international audience of young scientists, clinicians and leading experts to accelerate the prevention and precision medicine approaches for blood cancers. The workshop will provide new starting points to better understand tumour evolution, its mutability, plasticity, and adaptation at the single-cell level, and discuss cutting-edge techniques, including artificial intelligence, computational modelling and 3D culture systems. Registration closes on 15 February.
| |
|
---|
|
|
|
|
What did you think of this email? |
|
| |
|
|
| Together we are beating cancer |
| | |
---|
|
|
|
| You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here. Your details are safe with us. Check out our Privacy Policy. Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise. This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|